Key points on phenytoin teratogen risk
Phenytoin, an older antiepileptic drug, is a known human teratogen when used during pregnancy and is associated with a pattern of congenital differences collectively described as fetal hydantoin syndrome, which can include facial features changes, growth differences, fingernail and digital anomalies, and neurodevelopmental considerations. This evergreen explainer summarizes current evidence on mechanisms, specific malformations, and practical guidance for people with epilepsy who are planning pregnancy or are already pregnant. The focus is on what is well established, how teams typically approach risk assessment, and which clinical actions—before conception and during pregnancy—can meaningfully reduce harm.
What does teratogen mean in practice
A teratogen is an agent that can disturb fetal development when exposure occurs during pregnancy. For phenytoin, the clinical term fetal hydantoin syndrome captures a recognizable pattern of findings, although individual expression is variable. Key features, often summarized from clinical series, include:
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Facial phenotype | Dysmorphic features such as broad nasal bridge, wide anterior fontanelle, low nasal bridge, short nose, epicanthal folds, wide mouth, and thickened upper lip | Clinical case series and reviews |
| Growth parameters | Prenatal and postnatal growth deficiency, including microcephaly in some infants | Clinical series and reviews |
| Digital and nail anomalies | Hypoplastic or absent distal phalanges, fingernail hypoplasia | Clinical series and reviews |
| Congenital heart and other organ anomalies | Increased risk of cardiovascular and other structural defects compared with general population | Epidemiological and registry studies |
| Neurodevelopment and behavior | Risk of neurodevelopmental differences and cognitive outcomes that vary; multifactorial with genetics and other exposures | Longitudinal cohort studies |
Not every child exposed to phenytoin will show all features, and the severity can vary. The pattern is most consistent when multiple features coexist, and clinical evaluation can confirm whether findings align with fetal hydantoin syndrome.
How phenytoin may cause birth defects: current understanding
The mechanisms by which phenytoin may act as a teratogen are not fully defined but are thought to involve effects on folate metabolism, oxidative stress, and modulation of voltage-gated sodium channels during critical phases of organogenesis. Unlike some newer antiepileptic drugs with extensive pregnancy exposure registries and prospective data, phenytoin has decades of observational data supporting its teratogenicity. The fetal hydantoin syndrome is attributed primarily to in utero exposure, with recognizable dysmorphic and growth-related features reported at higher frequencies than in the background population.
Epidemiology, absolute risk, and what the numbers mean
Population-based studies and antiepileptic drug pregnancy registries consistently report elevated rates of major congenital malformations among offspring exposed to phenytoin in utero compared with unexposed pregnancies. Typical absolute risks fall in ranges reported across large cohorts:
| Metric | Estimate or Range | Context |
|---|---|---|
| Major congenital malformations (any) | 4–8% or higher compared with ~2–3% in general population | Registries and cohort studies; varies by regimen and polypharmacy |
| Fetal hydantoin syndrome features | Higher likelihood with first-trimester exposure; phenotype varies | Case series; not 100% penetrant |
| Neurodevelopmental outcomes | Variable; some studies report increased risk of cognitive and behavioral differences | Influenced by genetics, polypharmacy, maternal seizure control, and other factors |
These ranges illustrate that exposure substantially increases the likelihood of structural differences compared with baseline, but outcomes are heterogeneous. Discussing individual risk with a neurologist and obstetric team familiar with antiepileptic drug use is essential.
Clinical guidance before conception and during pregnancy
For people who take phenytoin and are planning pregnancy or discover pregnancy, the cornerstone of care is coordinated preconception counseling and early obstetric involvement. Recommendations typically emphasize:
- Preconception review of antiepileptic regimen, with evaluation of whether seizure control allows for potential simplification or substitution to a medication with a more favorable reproductive safety profile when clinically appropriate.
- High-dose folic acid supplementation (often 4–5 mg/day) before conception and during pregnancy, unless contraindicated, to help mitigate some of the folate-related risk associated with enzyme-inducing antiepileptic drugs.
- Early and regular prenatal care, including detailed anatomical ultrasound and, when indicated, fetal echocardiography to monitor for structural anomalies.
- Use of pregnancy outcome registries and maintaining seizure diaries to support both clinical care and research evidence.
- Avoidance of additional teratogenic exposures such as valproate, and careful review of other medications by the treating team.
Decisions about whether to continue, adjust, or switch medications must balance seizure control, maternal safety, and potential fetal risk, and are best made with a neurologist and obstetrician who know the full clinical picture.
When changes to antiepileptic medication are considered
In many cases, the choice to modify medication is individualized. Factors that commonly influence decisions include seizure frequency and type, prior response to other agents, mood and cognition effects, and access to specialized care. If a switch is under consideration, it is typically done gradually and with close monitoring to minimize the risk of breakthrough seizures, which also carry risks for both the birthing person and the developing fetus. No change in therapy should be made without input from the prescribing neurologist.
Pediatric follow-up and long-term considerations
Children exposed to phenytoin in utero should be monitored by a pediatric team experienced in neurodevelopmental assessment. Early intervention services can support motor, cognitive, language, and behavioral needs if they arise. Regular visits to evaluate growth, neurodevelopment, and hearing or vision concerns are often recommended, along with coordination between neurology, pediatrics, and allied health providers.
When to seek immediate medical care
During pregnancy, seek prompt medical or obstetric attention for new or worsening seizures, signs of poor fetal movement, heavy vaginal bleeding, severe headache, visual changes, or persistent vomiting. These findings may signal urgent maternal or fetal concerns and require in-person evaluation regardless of medication history. Any decision about continuing or adjusting phenytoin during pregnancy should be made by the clinical team managing the pregnancy and seizure disorder.
Bottom line on phenytoin and teratogen risk
Phenytoin is a recognized teratogen associated with fetal hydantoin syndrome and an increased risk of major congenital malformations compared with the general population. Careful preconception counseling, high-dose folic acid, early and consistent prenatal monitoring, and a balanced approach to antiepileptic medication management can meaningfully reduce risks while supporting seizure control. Because management is highly individualized, ongoing collaboration with neurology and obstetrics is the most reliable path to safe outcomes.